IL1B and TNF receptor 1-associated periodic fever syndrome: Another transcriptomic study demonstrated that the treatment with a human anti-IL-1β monoclonal antibody (Canakinumab) reversed the overexpression of inflammatory response genes including IL-1β, suggesting the central role of IL-1β in the TRAPS pathogenesis (126).